Swanson, D. A., Orovan, W. L., Johnson, D. E., & Giacco, G. (1981). Osseous metastases secondary to renal cell carcinoma. Urology, 18, 556–561. https://doi.org/10.1016/0090-4295(81)90455-6

Article  CAS  PubMed  Google Scholar 

Harries, M., Taylor, A., Holmberg, L., Agbaje, O., Garmo, H., Kabilan, S., & Purushotham, A. (2014). Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. Cancer Epidemiology, 38, 427–434. https://doi.org/10.1016/j.canep.2014.05.005

Article  CAS  PubMed  Google Scholar 

Li, J., Zhu, H., Sun, L., Xu, W., & Wang, X. (2019). Prognostic value of site-specific metastases in lung cancer: A population based study. Journal of Cancer, 10, 3079–3086. https://doi.org/10.7150/jca.30463

Article  PubMed  PubMed Central  Google Scholar 

Carlin, B. I., & Andriole, G. L. (2000). The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer, 88, 2989–2994. https://doi.org/10.1002/1097-0142(20000615)88:12+%3c2989::AID-CNCR14%3e3.0.CO;2-Q

Article  CAS  PubMed  Google Scholar 

Gong, Y., Zhang, J., Ji, P., Ling, H., Hu, X., & Shao, Z.-M. (2018). Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis. Cancer Medicine, 7, 4156–4169. https://doi.org/10.1002/cam4.1668

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grünwald, V., Eberhardt, B., Bex, A., Flörcken, A., Gauler, T., Derlin, T., Panzica, M., Dürr, H. R., Grötz, K. A., Giles, R. H., von Falck, C., Graser, A., Muacevic, A., & Staehler, M. (2018). An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nature Reviews Urology, 15, 511–521. https://doi.org/10.1038/s41585-018-0034-9

Article  PubMed  PubMed Central  Google Scholar 

Turpin, A., Duterque-Coquillaud, M., & Vieillard, M.-H. (2020). Bone metastasis: Current state of play. Translational Oncology, 13, 308–320. https://doi.org/10.1016/j.tranon.2019.10.012

Article  PubMed  Google Scholar 

Zhang, X.H.-F., Wang, Q., Gerald, W., Hudis, C. A., Norton, L., Smid, M., Foekens, J. A., & Massagué, J. (2009). Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell, 16, 67–78. https://doi.org/10.1016/j.ccr.2009.05.017

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arriaga, J. M., Panja, S., Alshalalfa, M., Zhao, J., Zou, M., Giacobbe, A., Madubata, C. J., Kim, J. Y., Rodriguez, A., Coleman, I., Virk, R. K., Hibshoosh, H., Ertunc, O., Ozbek, B., Fountain, J., Jeffrey Karnes, R., Luo, J., Antonarakis, E. S., Nelson, P. S., … Abate-Shen, C. (2020). A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nature Cancer, 1, 1082–1096. https://doi.org/10.1038/s43018-020-00125-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Decroisette, C., Monnet, I., Berard, H., Quere, G., Le Caer, H., Bota, S., Audigier-Valette, C., Geriniere, L., Vernejoux, J.-M., & Chouaid, C. (2011). Epidemiology and treatment costs of bone metastases from lung cancer: A French prospective, observational, multicenter study (GFPC 0601). Journal of Thoracic Oncology, 6, 576–582. https://doi.org/10.1097/JTO.0b013e318206a1e3

Article  PubMed  Google Scholar 

Vignani, F., Bertaglia, V., Buttigliero, C., Tucci, M., Scagliotti, G. V., & Di Maio, M. (2016). Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer Treatment Reviews, 44, 61–73. https://doi.org/10.1016/j.ctrv.2016.02.002

Article  CAS  PubMed  Google Scholar 

Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., Eisen, T., & Horwich, A. (2014). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 25, iii49–iii56. https://doi.org/10.1093/annonc/mdu259

Article  PubMed  Google Scholar 

Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., & Peters, S. (2017). Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 28, iv1–iv21. https://doi.org/10.1093/annonc/mdx222

Article  CAS  PubMed  Google Scholar 

Parker, C. C., James, N. D., Brawley, C. D., Clarke, N. W., Hoyle, A. P., Ali, A., Ritchie, A. W. S., Attard, G., Chowdhury, S., Cross, W., Dearnaley, D. P., Gillessen, S., Gilson, C., Jones, R. J., Langley, R. E., Malik, Z. I., Mason, M. D., Matheson, D., Millman, R., … Sydes, M. R. (2018). Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial. The Lancet, 392, 2353–2366. https://doi.org/10.1016/S0140-6736(18)32486-3

Article  Google Scholar 

Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 30, 1194–1220. https://doi.org/10.1093/annonc/mdz173

Article  CAS  PubMed  Google Scholar 

Michielin, O., van Akkooi, A. C. J., Ascierto, P. A., Dummer, R., & Keilholz, U. (2019). Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †. Annals of Oncology, 30, 1884–1901. https://doi.org/10.1093/annonc/mdz411

Article  CAS  PubMed  Google Scholar 

Argilés, G., Tabernero, J., Labianca, R., Hochhauser, D., Salazar, R., Iveson, T., Laurent-Puig, P., Quirke, P., Yoshino, T., Taieb, J., Martinelli, E., & Arnold, D. (2020). Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 31, 1291–1305. https://doi.org/10.1016/j.annonc.2020.06.022

Article  PubMed  Google Scholar 

Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Schil, P. E. V., Hellmann, M. D., & Peters, S. (2018). Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 29, iv192–iv237. https://doi.org/10.1093/annonc/mdy275

Article  CAS  PubMed  Google Scholar 

Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020). Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 31, 1119–1134. https://doi.org/10.1016/j.annonc.2020.06.011

Article  CAS  PubMed  Google Scholar 

Gennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., Im, S.-A., Krug, D., Kunz, W. G., Loi, S., Penault-Llorca, F., Ricke, J., Robson, M., Rugo, H. S., Saura, C., … Harbeck, N. (2021). ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆. Annals of Oncology, 32, 1475–1495. https://doi.org/10.1016/j.annonc.2021.09.019

Article  CAS  PubMed  Google Scholar 

James, N. D., Pirrie, S. J., Pope, A. M., Barton, D., Andronis, L., Goranitis, I., Collins, S., Daunton, A., McLaren, D., O’Sullivan, J., Parker, C., Porfiri, E., Staffurth, J., Stanley, A., Wylie, J., Beesley, S., Birtle, A., Brown, J., Chakraborti, P., … Billingham, L. J. (2016). Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with Strontium-89, zoledronic acid, or both: The TRAPEZE randomized clinical trial. JAMA Oncology, 2, 493–499. https://doi.org/10.1001/jamaoncol.2015.5570

Article  PubMed  Google Scholar 

Gueiderikh, A., Ung, M., Lazarovici, J., Danu, A., Ghez, D., Saleh, K., Dragani, M., Noël, N., Bigenwald, C., Willekens, C., Ribrag, V., Michot, J.-M., & Martin, V. (2023). Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases. Cancer/Radiothérapie. https://doi.org/10.1016/j.canrad.2023.04.004

Article  PubMed  Google Scholar 

Gillespie, E. F., Yang, J. C., Mathis, N. J., Marine, C. B., White, C., Zhang, Z., Barker, C. A., Kotecha, R., McIntosh, A., Vaynrub, M., Bartelstein, M. K., Mitchell, A., Guttmann, D. M., Yerramilli, D., Higginson, D. S., Yamada, Y. J., Kohutek, Z. A., Powell, S. N., Tsai, J., & Yang, J. T. (2023). Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: A multicenter, randomized phase II clinical trial. Journal of Clinical Oncology, 42, 38. https://doi.org/10.1200/JCO.23.00753

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hussain, A., Lee, R. J., Graff, J. N., & Halabi, S. (2019). The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone. Critical Reviews in Oncology/Hematology, 139, 108–116. https://doi.org/10.1016/j.critrevonc.2019.04.020

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stinauer, M. A., Kavanagh, B. D., Schefter, T. E., Gonzalez, R., Flaig, T., Lewis, K., Robinson, W., Chidel, M., Glode, M., & Raben, D. (2011). Stereotactic body radiation therapy for melanoma and renal cell carcinoma: Impact of single fraction equivalent dose on local control. Radiation Oncology, 6, 34. https://doi.org/10.1186/1748-717X-6-34